Table 1.

Baseline characteristics

	Patients (N=31)
Median age, years (range)	71 (65–84)
Aged 70 years or older	23 (74%)
Sex
Male	19 (61%)
Female	12 (39%)
Diagnosis
Chronic lymphocytic leukaemia	29 (94%)
Small lymphocytic lymphoma	2 (6%)
Time from initial diagnosis to study entry, months	57·3 (0·7–369·8, 24·8–89·3)
Rai stage at treatment
I	8 (26%)
II	5 (16%)
III	6 (19%)
IV	11 (35%)
Missing data	1 (3%)
ECOG performance status
0	23 (74%)
1	8 (26%)
Bulky nodes (≥5 cm)	6 (19%)
Unmutated IgHV	15 (48%)
Interphase cytogenetics*
Del(17p13.1)	2 (6%)
Del(11q22.3)	1 (3%)
Del(13q14)	17 (55%)
Trisomy 12	8 (26%)
β2 microglobulin concentration
>3 mg/L	8 (26%)
≤3 mg/L	23 (74%)
Cytopenia
Absolute neutrophil count <1500 cells per μL	1 (3%)
Haemoglobin <110 g/L	11 (35%)
<100 000 platelets per μL	12 (39%)
Lactate dehydrogenase
<350 U/L	22 (71%)
≥350 U/L	9 (29%)
Zap-70
Methylated	14 (45%)
Non-methylated	16 (52%)
Missing	1 (3%)

Data are median (range, IQR) or n (%), unless otherwise stated. ECOG=Eastern Cooperative Oncology Group. IgHV=immunoglobulin variable heavy chain. Del=deletion.

^*Cutoffs were defined per the assay specifications as done in the central laboratory.